{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-21-031170","form_type":"8-K","ticker":"GLSI","cik":"0001799788","company_name":"Greenwich LifeSciences, Inc.","filed_at":"2021-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.193811+00:00","generated_at":"2026-06-28T01:47:19.639834+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Greenwich LifeSciences reports 5-year GP2 Phase IIb data: baseline immune response predicts recurrence","bullets":["22.8% of 145 patients had positive baseline DTH response to GP2; 24.2% recurrence rate over 5 years (median 99 days).","Patients without baseline response had 12.5% recurrence rate with median time to recurrence of 438 days.","HER2+ patients completing GP2 primary series showed 100% DFS vs 89.4% for placebo (p=0.0338) over 5 years.","GP2 treatment was well tolerated with no serious adverse events attributed to GLSI-100.","Company plans Phase III trial in 2022 and exploration of GP2-specific CAR-T cell candidates."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-21-031170","json":"https://secwatch.observer/filing/0001493152-21-031170.json","markdown":"https://secwatch.observer/filing/0001493152-21-031170.md","text":"https://secwatch.observer/filing/0001493152-21-031170.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799788/000149315221031170/0001493152-21-031170-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799788/000149315221031170/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T01:47:19.639834+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}